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Dr Giancarlo Roviaro (Milan, Italy). I would like to thank Dr
Schuchert and coworkers for presenting this good experience in an-
atomic segmentectomies, which once again seems to confirm the
validity of VATS in the treatment of early-stage lung cancer. The
paper is good, well done, and the analysis of the patients, of the out-
comes and of survival, is totally correct. Before asking you my
questions, I would like to make some personal observations regard-
ing the so-called VATS lobectomies and anatomic resections.
When, 17 years ago, I started my experience of thoracoscopic lo-
bectomies, the majority of thoracic surgeons in the United States
(except 10, or maximum 20, and some of them are present here to-
day) were completely against these operations, considering these
operations absurd, catastrophic, and oncologically not correct. In
these years, the technique has surely been improved. Many authors,
in order to reduce the technical difficulties, have presented different
options to perform this operation, and at this moment I don’t know
what a VATS lobectomy really is. I don’t know how many types of1324 The Journal of Thoracic and Cardiovascular SurVATS lobectomy exist, and when it’s possible to call them VATS
lobectomies, thoracoscopic lobectomies, or open lobectomies only
because the thoracoscope is introduced with a 10-cm, 15-cm inci-
sion and a wide incision of intercostal muscles using forceps,
Duval, and all the other instrumentation for conventional surgery.
In the literature, many surgeons, with perfect selection of pa-
tients and good experience, have a high conversion rate. On the
other hand, other surgeons don’t have conversions and consider
these so-called VATS lobectomies the ideal operation for every pa-
tient. They also present sleeve lobectomies in this way. Are these
the same operation or must we change the name to avoid the con-
fusion?
In your paper, Dr Schuchert, you have written that, in the early
’90s, the anatomic open segmentectomies fell out of favor due to
technical difficulties. Up to now, open sublobar resections have
been accepted as an appropriate alternative to lobectomy in com-
promised patients. Recently, many authors have presented good re-
sults after wedge resection, similar to those after lobectomy, even
for fit patients.
My question is, when CT scan discovers a peripheral lesion less
than 1 or 2 cm, how do you decide whether to perform a wedge re-
section instead of a segmentectomy or a formal lobectomy? How do
you select the open versus the thoracoscopic approach, and how
many VATS or open lobectomies did you perform in comparison
with 225 segmentectomies?
Dr Schuchert. Thank you, Dr Roviaro, for your comments.
Addressing the first question regarding small lesions, when
1-2 cm nodules are identified and are confined to a specific bron-
chopulmonary segment, we would consider performing an ana-
tomic segmentectomy in an effort to preserve function, especially
in elderly patients or patients in whom lobectomy may be consid-
ered a higher risk option. We generally prefer anatomic segmentec-
tomy over a simple wedge resection because of the concern
regarding an increased local recurrence rate associated with wedges
compared to segments. El-Sherif and colleagues found a 3.8% ver-
sus 14.5% locoregional recurrence rate when comparing anatomic
segmentectomy versus wedge resection (Ann Surg Oncol.
2007;14:2400-5). So when performing a sublobar resection for
small lesions confined to a distinct bronchopulmonary segment,
we would prefer a formal anatomic segmentectomy as opposed to
a wedge. If we encounter a larger lesion (>3 cm) that crosses seg-
mental boundaries, or if N1 lymph node involvement is suspected
or documented, a lobectomy would be advocated.
The second question relates to the open versus VATS approach.
I think a lot of that comes down to technical experience and surgical
judgment. The principal investigators in this study have extensive
experience in VATS techniques and have developed a technical ap-
proach that facilitates resident teaching and is flexible in implemen-
tation, whether performing a segmentectomy or lobectomy. Of
primary importance, great effort is undertaken to avoid compromis-
ing the fundamental principles of the procedure, and to try to emu-
late as specifically as possible the open approach when using the
VATS technique. We use many of the same dissection instruments
and stapling equipment, perform the same type of selective ap-
proach to the hilar structures, and try to achieve the exact same sur-
gical margins that we would under open conditions.
During the same period of this study, our group has performed
approximately 250 lobectomies for pathological stage 1 non–gery c December 2009
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majority have been performed open. Over recent years, however,
there has been a significant increase in the use of the VATS ap-
proach for lobectomy.
Dr Roviaro. My second question regards the old problem of
lymphadenectomy and videothoracoscopy. Is lymphadenectomy
feasible in the same way as in open surgery, or must we exclude
the patients in which the frozen section during the operation dem-
onstrated N1 or N2? As you know, lymph node enlargement is not
a sure sign of malignancy. On the other hand, small lymph nodes
can be metastatic. Do you always perform a complete lymphade-
nectomy or do you sample each level, or else do you just harvest
local lymph nodes? Does your attitude differ in open or in the vid-
eothoracoscopic approach?
Dr Schuchert. Our group tends to perform systematic lymph
node sampling of the standard stations on each side. We do place
an importance on obtaining an adequate sample from each station.
The results of the ACOSOG Z0030 trial will add important infor-
mation regarding the utility of lymph node dissection versus sam-
pling in the setting of clinical stage 1 non–small-cell lung cancer.
Dr Roviaro. For my last question, in my experience I have per-
formed a limited resection only in very compromised patients. Sur-
vival rates have been significantly decreased due to causes
unrelated to cancer, whereas recurrence was not always a determi-
nant of the decreased survival in these patients. What has been the
impact of non–cancer-related causes on your survival, and, at the
end, why did you operate on a 100-year-old patient?
Dr Schuchert. The majority of deaths in our group were due to
noncancer causes. Those that were due to malignancy were more
commonly associated with disseminated disease. This pattern sup-
ports the notion that a distinct survival advantage might not be at-
tained by doing a more aggressive resection in this select group of
patients in whom the disease exhibits a more systemic biology.
Advanced age is viewed as a relative contraindication in select-
ing patients for surgery. We certainly encounter elderly patients
who are extremely fit. We prefer to focus on a patient’s physiologic
age, their estimated ability to withstand the procedure, and their
personal disposition toward pursuing surgery aggressively. It’s an
individualized decision when choosing to operate on an elderly pa-
tient.
Dr Roviaro. Thank you.
Dr L. Penfield Faber (Chicago, Ill). I saw those indications up
there for segmental resection and I am very pleased to say that I’m
happy I qualify. Dr Jensik and Dr Faber are very pleased to see
that, indeed, there is a renewed interest in segmental resection.
Our first series in 1973 with 65 cases (it was subsequently ex-
panded to over 350 cases) had a mortality rate of 1.6% and a 5-
year actuarial survival rate of 56%. Now, in those days, we didn’t
stage as well as we stage nowadays, and certainly I think if we had
staged better, we had measured the size of the tumor, and taken out
all the lymph nodes that should be taken out, survival would have
been better. But with new techniques, stapling techniques, indeed I
think that morbidity and mortality will be much less. I am a littleThe Journal of Thoracic and Cardisappointed that you reserve it for individuals over the age of 75
because I think the operation you are describing has the potential
to be an operation of choice for the lesion 2 cm and less. We must
remember that, in the lung cancer study group, 40 wedges were
included in that series. The end result was that survival was the
same despite an increase in local recurrence. I would certainly
want to say that a segmentectomy by stapling technique, VATS
technique, should not be a deep wedge resection, and it must be
an anatomic resection—pulmonary artery, pulmonary bronchus,
and lymph node resection.
So my question is, as you are doing your VATS segmentectomy
and you encounter a lymph node at level 11 or level 12 and frozen
section reveals metastatic microcancer, because we’re going to hear
a paper about understaging, what do you do then?
Dr Schuchert.When we encounter a level 11 or 12 lymph node
during the course of dissection, we would definitely consider lobec-
tomy in an effort to obtain an R0 resection. In all surgical resec-
tions, we also carefully assess the standard mediastinal lymph
node stations so that we accurately stage those patients.
Dr Raja Flores (New York, NY). First of all, I want to state that I
am a huge proponent of VATS lobectomy and VATS segmentec-
tomy. However, many surgeons who support open thoracotomy
will frequently state that there is a huge selection bias when we per-
form these studies of open and VATS patients, which leads me to
conversion. The number of patients that you presented, I’m sure
there must have been some conversions in there.
Dr Schuchert. Yes.
Dr Flores. What was your conversion rate from VATS seg-
mentectomy to open segmentectomy and from VATS segmentec-
tomy to VATS lobectomy, and how did you handle that in your
analysis?
Dr Schuchert. There were 2 conversions in this series, both for
bleeding. I do not have the answer as to how many patients started
off as a segmentectomy and went on to lobectomy because the pa-
tients analyzed in this series were only those who ended up being
treated ultimately with segmentectomy. Patients undergoing
a VATS segmentectomy who underwent conversion to an open ap-
proach were included in the VATS cohort because the intention
was to treat via VATS.
Dr Tomasz Grodzki (Szczecin, Poland). I would like to con-
gratulate you on an excellent paper. I think segmentectomy is a sur-
gery of choice for really small tumors. My question regards the time
of surgery. Open segmentectomy took 2½ hours in your hands. My
simple question is, what have you been doing there so long?
Dr Schuchert. Your comments are appreciated. I think a lot of
that is a testament to our faculty’s dedication to teaching and train-
ing young personnel to do this procedure. Anatomic segmentec-
tomy is a procedure that residents do not have as much
experience with compared to lobectomy. There are different ana-
tomic and intraoperative decision-making issues that have to be
considered. Like most minimally invasive procedures, operative
time tends to decrease with surgeon experience.
Dr Grodzki. Thank you.diovascular Surgery c Volume 138, Number 6 1325
